BICO Group AB (FRA:49Z)

Q4 2025 BICO Group AB Earnings Call Transcript

Feb 18, 2026 / 09:00AM GMT

Release Date Price: €1.79 (+12.41%)

Transcript

Key Points

Positve

BICO Group AB (CLLKF) finished 2025 with double-digit organic sales growth in lab automation and a strengthened cash position.
The company successfully raised new capital in January 2026, enabling further investments to support growth.
BICO's lab automation solutions have significantly improved productivity and reliability for pharma customers, reducing development time and increasing equipment utilization.
The company has a strong R&D pipeline with multiple product launches planned, including innovative solutions like GoSimple and AI-driven tools.
BICO's strategic focus on lab automation and customer-centric product portfolio provides a solid foundation for future growth.

Negative

The US academia segment faced significant challenges due to NIH funding cuts, impacting sales negatively.
BICO experienced a negative organic sales growth of 8% for the full year 2025.
FX headwinds with a weaker US dollar and EUR affected margins adversely.
The company's adjusted EBITDA margin was low at 0.3% for the full year 2025.
The first half of 2025 was weak for Biosero, impacting full-year results despite improvements in the second half.

Operator

Welcome to BICO Q4 2025 report presentation. (Operator Instructions)

Now I will hand the conference over to the speakers, CEO Maria Force and CFO Jacob Thordenberg. Please go ahead.

Maria Forss

BICO Group AB - President, Chief Executive Officer

Hello and welcome to BICO Group's quarter four 2025 earnings call. I'm Maria Forss, President and CEO, and I will, together with BICO's CFO Jacob Thornberg, present this year's end report.

Here's today's agenda. I will open today's session by summarizing 2025 and also describe how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customers' challenges.

Following that, I will summarize the full year 2025 as well as quarter four FY25, and Jacob will then present the group's financial performance. We will then proceed and comment on our performance in the two business areas, life science solutions and lab automation.

I will also comment on our R&D pipeline with our ongoing product development

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.